1. Home
  2. TLK vs UTHR Comparison

TLK vs UTHR Comparison

Compare TLK & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TLK
  • UTHR
  • Stock Information
  • Founded
  • TLK 1884
  • UTHR 1996
  • Country
  • TLK Indonesia
  • UTHR United States
  • Employees
  • TLK N/A
  • UTHR N/A
  • Industry
  • TLK Telecommunications Equipment
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • TLK Telecommunications
  • UTHR Health Care
  • Exchange
  • TLK Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • TLK 16.1B
  • UTHR 13.8B
  • IPO Year
  • TLK 1995
  • UTHR 1999
  • Fundamental
  • Price
  • TLK $18.40
  • UTHR $301.50
  • Analyst Decision
  • TLK
  • UTHR Buy
  • Analyst Count
  • TLK 0
  • UTHR 13
  • Target Price
  • TLK N/A
  • UTHR $379.69
  • AVG Volume (30 Days)
  • TLK 636.6K
  • UTHR 602.5K
  • Earning Date
  • TLK 08-19-2025
  • UTHR 07-30-2025
  • Dividend Yield
  • TLK 5.69%
  • UTHR N/A
  • EPS Growth
  • TLK N/A
  • UTHR 17.94
  • EPS
  • TLK 0.01
  • UTHR 25.63
  • Revenue
  • TLK $9,097,469,437.00
  • UTHR $3,077,800,000.00
  • Revenue This Year
  • TLK $3.12
  • UTHR $14.37
  • Revenue Next Year
  • TLK $3.19
  • UTHR $6.59
  • P/E Ratio
  • TLK $12.67
  • UTHR $11.79
  • Revenue Growth
  • TLK N/A
  • UTHR 17.62
  • 52 Week Low
  • TLK $13.15
  • UTHR $266.98
  • 52 Week High
  • TLK $21.00
  • UTHR $417.82
  • Technical
  • Relative Strength Index (RSI)
  • TLK 70.28
  • UTHR 53.58
  • Support Level
  • TLK $17.88
  • UTHR $296.57
  • Resistance Level
  • TLK $18.34
  • UTHR $307.49
  • Average True Range (ATR)
  • TLK 0.24
  • UTHR 9.26
  • MACD
  • TLK 0.08
  • UTHR 0.85
  • Stochastic Oscillator
  • TLK 99.19
  • UTHR 82.55

About TLK PT Telekomunikasi Indonesia Tbk

PT Telkom Indonesia (Persero) Tbk is the integrated telecommunications provider in Indonesia. The company is focusing on dividing business into 3 Digital Business Domains namely, digital connectivity, digital platform, and digital services. It also provides a wide range of other communication services, including telephone network, interconnection services, multimedia, data and internet communication-related services, satellite transponder leasing, leased line, intelligent network and related services, cable television, and VoIP services. The group derives revenue from product lines: Mobile, Consumer, Enterprise, WIB and Others.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: